Shares of Retrophin, Inc. (NASDAQ:RTRX) have received an average recommendation of “Buy” from the seven brokerages that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $35.00.

RTRX has been the subject of a number of research analyst reports. Zacks Investment Research lowered shares of Retrophin from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 3rd. ValuEngine lowered shares of Retrophin from a “hold” rating to a “sell” rating in a research note on Friday, June 2nd. Finally, TheStreet raised shares of Retrophin from a “d” rating to a “c-” rating in a research note on Friday, May 12th.

Shares of Retrophin (RTRX) traded up 5.66% during mid-day trading on Friday, hitting $21.83. The company had a trading volume of 373,941 shares. The company’s market capitalization is $837.94 million. Retrophin has a one year low of $15.55 and a one year high of $24.57. The firm’s 50-day moving average price is $19.89 and its 200 day moving average price is $19.04.

Retrophin (NASDAQ:RTRX) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.10. The firm had revenue of $38.80 million during the quarter, compared to analyst estimates of $37.36 million. Retrophin had a negative net margin of 48.74% and a negative return on equity of 7.31%. Retrophin’s quarterly revenue was up 16.5% on a year-over-year basis. During the same period last year, the firm earned $0.07 EPS. Analysts predict that Retrophin will post ($1.13) earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. Weiss Multi Strategy Advisers LLC acquired a new position in Retrophin during the first quarter worth approximately $185,000. Point72 Asset Management L.P. increased its position in Retrophin by 133.8% in the first quarter. Point72 Asset Management L.P. now owns 964,800 shares of the biopharmaceutical company’s stock worth $17,810,000 after buying an additional 552,065 shares in the last quarter. Virginia Retirement Systems ET AL increased its position in Retrophin by 99.2% in the first quarter. Virginia Retirement Systems ET AL now owns 75,100 shares of the biopharmaceutical company’s stock worth $1,386,000 after buying an additional 37,400 shares in the last quarter. FMR LLC increased its position in Retrophin by 24.8% in the first quarter. FMR LLC now owns 1,958,875 shares of the biopharmaceutical company’s stock worth $36,161,000 after buying an additional 389,714 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in Retrophin during the fourth quarter worth approximately $387,000.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/retrophin-inc-nasdaqrtrx-given-average-recommendation-of-buy-by-brokerages/1480184.html.

About Retrophin

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.